Kuru: research | The Generative Brain

Kuru research now matters mostly for what the epidemic did to the genetics of the exposed population, and for what that genetic finding is being developed into. The disease itself and its history are covered on kuru and the more detailed page.

What did the epidemic select for?

Mead and colleagues carried out genetic, clinical and genealogical assessment of more than 3000 people from Eastern Highland populations of Papua New Guinea, including 709 who had taken part in mortuary feasts, of whom 152 later died of kuru.

Survivors of the epidemic were predominantly heterozygous at codon 129, the previously known resistance factor. The new finding was G127V, a variant present only in people from the kuru region, absent in kuru patients and in unexposed populations worldwide, and carried by half of the otherwise susceptible methionine homozygous women from the area of highest exposure. Genealogical analysis found significantly lower kuru incidence in pedigrees carrying the allele than in geographically matched control families.

The authors’ conclusion is specific: 127V is an acquired prion disease resistance factor selected during the epidemic, rather than a pathogenic mutation that could have started it. The evidence for protection is population-level and genealogical, which is the strongest design available for a vanished epidemic and still not an experimental demonstration in people.

What does the variant do to the protein?

Zheng and colleagues solved and compared solution structures of G127V-mutated human PrP residues 91 to 231 and the wild-type protein. In the mutant, atomic distances between the two short strands formed by residues Tyr128 to Gly131 and Val161 to Arg164 are extended, the Tyr128 side chain is rearranged by steric hindrance from the larger valine side chain, and the extended alpha-1 helix moves closer to the alpha-2 and alpha-3 helices. NMR dynamics showed significant conformational exchange at Tyr128, Gly131 and Tyr163, and molecular dynamics simulations suggested that the mutant resists forming stable beta-sheets and dimers.

Work on dimerisation has not been consistent. Sangeetham and colleagues reported that G127V inhibited dimer formation in vitro but that the effect was not evident in a mammalian cell culture system, so the simulation-derived dimer mechanism should be treated as unsettled.

Can the variant be used as a therapy?

Two 2026 reports take different routes to the same idea, both relying on the variant acting dominantly over wild-type protein.

Gatdula and colleagues used inducible expression of G126V PrP, the mouse equivalent, alongside wild-type PrP in CAD5 cells, and report dose-dependent prevention and suppression of prion infection. In CAD5 cells expressing bank vole PrP the protective effect covered a wide range of naturally and artificially derived strains, and the effect was reproduced in primary cerebellar astrocyte cultures. Prion resistance persisted after G126V expression had ceased, which they read as a sustained effect that could remove the need for continuous transgene expression. Anchorless recombinant G127V PrP retained potent dominant-negative activity, suggesting a route to a protein therapeutic.

Zerbes and colleagues delivered the variant in vivo. Knock-in mice whose Prnp had been replaced with bank vole Prnp were inoculated with RML prions and transduced retro-orbitally with a self-complementary AAV vector encoding anchorless bank vole PrP carrying V127, using a cross-correction design to work around AAV delivery limits. Transduced mice survived about 50 days longer than unprotected controls. Proteomic analysis indicated that the protection slowed the proteome changes of late-stage disease.

Both are proof-of-concept studies in cell lines and rodent models, with the in vivo work using a bank vole PrP background rather than human PrP and a laboratory mouse strain rather than human prions. A survival extension of about 50 days in RML-inoculated mice is a real effect and not a claim about people. No clinical trial of a G127V-based approach appears in the sources read here.

Sources for this page